SLC5A2 and diabetic kidney disease: In diabetic kidney disease (DKD), SGLT2 inhibitors slow progression by improving glycemic control through increased insulin sensitivity and glucose excretion, reducing albuminuria, and slowing the decline in estimated glomerular filtration rate (eGFR).